Crohn's Disease Clinical Trial
Official title:
Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With Vitamin D Deficiency，a Prospective Cohort Study
Aims:Prospectively observe the effects of Vitamin D drops supplementation on the chronic
course of Crohn's disease patients, analyze whether the effect of Vitamin D drops on CD
patients is affected by factors such as disease site, disease activity, treatment,
etc.Exploring the relationship between Fok I gene polymorphism and the efficacy of vitamin D
supplementation. Provide a certain theoretical basis for "precision treatment" for CD
patients in the future.
Design：It is a prospective cohort study. Investigators include a total of 60 participants
with CD according to the inclusion and exclusion criteria, and divide them into two groups to
assess their initial disease activity and detect related indicators. At the same
time，investigators detect the Fok I gene polymorphism in all participants.One group is given
Vitamin D drops 400IU per day orally, and the control group do not intervene. Participants'
disease activity is assessed at baseline and related indicators are determined. The disease
activity is re-evaluated at 2, 6, 14, 22, 30, and 38 weeks, and the serum indexes are
re-evaluated.Investigators use statistical methods to analyze whether Vitamin D drops
supplementation treatment can increase the serum 25 (OH) D level of CD participants who are
treated with infliximab, improve the condition of CD participants,relationship with Fok I
gene polymorphism，and analyze the effects of Vitamin D drops on participants with CD is
affected by factors such as disease site, disease activity, and treatment.
1. The research can be started only after approval by the Medical Ethics Committee of the
Second Affiliated Hospital of Wenzhou Medical University.
2. According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease"
formulated by the Beijing Conference in 2018 as a standard, patients with clear
diagnosis of CD are collected. Other diagnostic criterions include vitamin D deficiency
(<= 20ng / ml) and treatment with infliximab. Exclusion criteria include pregnancy,
breastfeeding, liver and kidney dysfunction, concurrent autoimmune diseases, and use of
antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes.
3. Assess disease activity of CD participants based on the "Simplified Crohn's disease
Activity Score".
4. General information about participants with CD is collected.
5. Detection of Fok I gene polymorphism using Snapshot technology.
6. The level of serum 25 (OH) D of participants is detected.
7. Serum C-reactive protein, erythrocyte sedimentation rate, albumin, calcium and
phosphorus levels are measured.
8. Develop a treatment plan for all participants.
9. Participants are divided into two groups, one group is given oral vitamin D drops 400IU/
d, and the other group do not intervene.
10. The disease activity is re-evaluated at 2, 6, 14, 22, 30, and 38 weeks, and the above
serum indexes are re-evaluated.
11. Follow-up for 38 weeks. By comparing the above indicators, observe that in the Han
population:
1. Can Vitamin D drops supplementation increase serum 25 (OH) D levels in patients
with CD who are treated with infliximab?
2. Can Vitamin D drops supplementation improve the condition of patients with CD who
are treated with infliximab?
3. Whether Fok I gene polymorphism affect the efficacy of Vitamin D drops
supplementation therapy?
4. Whether the effects of Vitamin D drops on CD patients who are treated with
infliximab is affected by factors such as disease site, disease activity,
treatment, etc ..
12. Through statistical analysis, comprehensive analysis of the effectiveness and safety of
Vitamin D drops supplementation in Han patients with CD who are treated with
infliximab，and its relationship with Fok I gene polymorphism, providing a theoretical
basis for further "precise treatment" intervention in inflammatory bowel disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
| Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
| Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
| Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
| Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
| Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
| Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
| Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
| Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
| Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
| Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
| Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
| Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
| Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
| Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
| Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
| Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
| Completed |
NCT01951326 -
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
|
Phase 3 |